Sudeep Pharma Ltd
Sudeep Pharma Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
The short version
The company expects to sustain growth similar to the strong performance seen over the last couple of years, aiming for continued 35%-40% growth. Management refrains from giving specific revenue growth guidance but aims to sustain the strong growth momentum achieved in recent years, around 35%-40%, with a stable margin profile.
From Sudeep Pharma Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company expects to sustain growth similar to the strong performance seen over the last couple of years, aiming for continued 35%-40% growth.
- Specialty ingredients, currently at ~40% capacity utilization, are anticipated to be a key growth driver over the next two years with increasing customer approvals.
- The pharma, food, and nutrition vertical, now with greenfield capacity coming online, is expected to ramp up utilization to 30%-40% by FY '28.
- Battery chemicals segment will start contributing revenue from FY '28, with phase-wise capacity scaling from 25,000 tons to potentially 100,000 tons depending on offtake agreements.
2 more points from Sudeep Pharma Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Sudeep Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Core Business (Pharma, Food Nutrition):
- Greenfield facility at Nandesari with 51,200 MT capacity, commissioning by March 2026 (Q4 FY '26).
- Majority of capex for this project already spent; residual INR 10-15 crores expected by April 2026.
- No significant further capex planned; existing capacity sufficient for growth.
- Specialty Ingredients:
- Currently 35%-40% utilization; no major capex planned.
- Growth driven by approvals and expansion in this segment.
- Battery Materials Project:
- Total capex approx. INR 550-600 crores for 100,000 tons capacity.
- Phase 1 (25,000 tons) capex approx. INR 300 crores, including land.
- Project completion expected in 18 months (early 2027 for phase 1).
2 more points from Sudeep Pharma Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sudeep Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Sudeep Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹182 Cr, net profit ₹49 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sudeep Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Arthneeti Pro · Annual
Sudeep Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sudeep Pharma Ltd Q3 FY26 results?
The company expects to sustain growth similar to the strong performance seen over the last couple of years, aiming for continued 35%-40% growth. Management refrains from giving specific revenue growth guidance but aims to sustain the strong growth momentum achieved in recent years, around 35%-40%, with a stable margin profile.
What is Sudeep Pharma Ltd share price analysis?
Sudeep Pharma Ltd currently shows a neutral. The stock trades at a P/E of 59.3 with a market cap of ₹10,831 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sudeep Pharma Ltd planning capital expenditure?
Core Business (Pharma, Food Nutrition): - Greenfield facility at Nandesari with 51,200 MT capacity, commissioning by March 2026 (Q4 FY '26). - Majority of capex for this project already spent; residual INR 10-15 crores expected by April 2026. - No significant further capex planned; existing capacity sufficient for growth. - Specialty Ingredients: - Currently 35%-40% utilization; no major capex planned. - Growth driven by approvals and expansion in this segment. - Battery Materials Project: - Total capex approx.
Keep Sudeep Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.